SCA
AMGN icon

Salient Capital Advisors’s Amgen AMGN Stock Holding History

Salient Capital Advisors’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,390
Closed -$208K – 249
2016
Q1 		$208K Sell
1,390
-100
-7% -$14.9K 0.01% 236
2015
Q4 		$242K Buy
+1,490
New +$234K 0.01% 231
2015
Q3 		– Sell
-1,435
Closed -$220K – 249
2015
Q2 		$220K Buy
+1,435
New +$230K ﹤0.01% 248

Other funds holding AMGN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Salient Capital Advisors's AMGN Position: Q2 2016 in Review

Salient Capital Advisors sold out of Amgen (AMGN) in Q2 2016, closing a stake of 1,390 shares — an estimated $208K sold.

Salient Capital Advisors first reported a position in AMGN in Q2 2015 and held it in 3 quarters. The position peaked at $242K in Q4 2015. 1,472 funds tracked by Wall St. Rank hold AMGN as of Q2 2016.

  • Salient Capital Advisors reported no remaining Amgen position as of Q2 2016 after selling out during the quarter.
  • Salient Capital Advisors sold 1,390 Amgen shares in Q2 2016, an estimated $208K.
  • Salient Capital Advisors first reported a position in Amgen in Q2 2015 and held it in 3 quarters.
  • Salient Capital Advisors's Amgen position peaked at $242K in Q4 2015.
  • 1,472 funds tracked by Wall St. Rank held Amgen as of Q2 2016.

Based on Salient Capital Advisors's 13F filing for Q2 2016, filed 5 Aug 2016.